Trends in lipid profiles in patients with psoriasis: a population-based analysis

Annals of Occupational and Environmental Medicine

Bharath Manu Akkara Veetil²  Eric L Matteson¹  Hilal Maradit-Kremers¹  Marian T McEvoy³  Cynthia S Crowson¹ 

[1] Department of Health Sciences Research, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

[2] Division of Rheumatology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

[3] Department of Dermatology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

关键词: Epidemiology;    Lipids;    Psoriasis;   

Others  :  814431
DOI  :  10.1186/1471-5945-12-20

 received in 2012-02-29, accepted in 2012-10-08,  发布年份 2012

【 摘 要 】

Background

Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles.

Methods

We compared changes in lipid profiles in a population based incident cohort of 689 patients with psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles.

Results

There were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the 5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort. Triglyceride (TG) levels were significantly higher (p<0.001), and HDL levels significantly lower (p=0.013) in patients with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering drugs between the two cohorts.

Conclusions

Patients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further exploration.

【 授权许可】

   
2012 Akkara Veetil et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kremers HM, McEvoy MT, Dann FJ, Gabriel SE: Heart disease in psoriasis. J Am Acad Dermatol 2007, 57:347-354.
• [2]Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM: Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010, 31:1000-1006.
• [3]Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, et al.: Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology (Basel, Switzerland) 2008, 217:27-37.
• [4]Kimball AB, Wu Y: Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol 2009, 48:1147-1156.
• [5]Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F: Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica chimica acta; international journal of clinical chemistry 2001, 303:33-39.
• [6]Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD: Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008, 88:561-565.
• [7]Tekin NS, Tekin IO, Barut F, Sipahi EY: Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007, 2007:78454.
• [8]Farshchian M, Zamanian A, Monsef AR, Mahjub H: Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007, 21:802-805.
• [9]Vahlquist C, Michaelsson G, Vessby B: Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987, 67:12-15.
• [10]Kurland LT, Molgaard CA: The patient record in epidemiology. Sci Am 1981, 245:54-63.
• [11]Maradit Kremers H, Crowson CS, Gabriel SE: Rochester epidemiology project: a unique resource for research in the rheumatic diseases. Rheum Dis Clin North Am 2004, 30:819-834. vii.
• [12]Maradit Kremers H, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL: The rochester epidemiology project: exploiting the capabilities for population-based research in rheumatic diseases. Rheumatology (Oxford) 2011, 50:6-15.
• [13]Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
• [14]Piskin S, Gurkok F, Ekuklu G, Senol M: Serum lipid levels in psoriasis. Yonsei Med J 2003, 44:24-26.
• [15]Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006, 298:321-328.
• [16]Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG: Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009, 145:700-703.
• [17]Gelfand JM, Mehta NN, Langan SM: Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011, 131:1007-1010.
• [18]Third Report of the National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
• [19]Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55:829-835.
• [20]Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE: Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010, 69:1310-1314.
• [21]Prodanovich S, Shelling ML, Federman DG, Kirsner RS: Cytokine milieu in psoriasis and cardiovascular disease may explain the epidemiological findings relating these 2 diseases. Arch Dermatol 2008, 144:1518-1519.
• [22]Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
• [23]Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ: More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161:1-7.
• [24]White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, et al.: Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years’ experience. J Clin Epidemiol 1996, 49:223-233.
• [25]Akgun S, Ertel NH, Mosenthal A, Oser W: Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 1998, 131:103-108.
• [26]Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al.: Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 2005, 294:1773-1781.